Rare POLE P286R-Mutated Lung Cancer Shows Dramatic Response to Immunotherapy
A case report describes the first hepatoid adenocarcinoma of the lung harboring a POLE P286R mutation, which drove hypermutation, mismatch ...
A case report describes the first hepatoid adenocarcinoma of the lung harboring a POLE P286R mutation, which drove hypermutation, mismatch ...
Researchers in Leipzig corrected a hidden error in a Bayesian network and found the transparent AI model matched real tumor ...
A retrospective cohort study of 215 patients finds that small node-negative triple-negative breast cancers show similar biology and outcomes across ...
A multicohort study finds that gastric tumors rich in PD-1 and LAG-3 double-positive CD8 T cells—an activated, pre-exhausted population—are linked ...
A systematic review of 116 case reports reveals that immune checkpoint inhibitors can trigger rare but often fatal heart complications, ...
The Phase 3 EVOKE-03/KEYNOTE-D46 trial found that sacituzumab govitecan plus pembrolizumab did not significantly improve progression-free or overall survival compared ...
A translational modelling study finds that PD-1 receptor occupancy does not predict immune activation during pembrolizumab therapy, challenging current dosing ...
A new cost-effectiveness analysis finds nivolumab plus ipilimumab may offer greater quality-adjusted life years at lower cost than pembrolizumab as ...
A Japanese study found that immune-related adverse events during checkpoint inhibitor therapy for advanced gastric cancer were independently linked to ...
Five-year results from the KEYNOTE-826 trial confirm that adding pembrolizumab to first-line chemotherapy delivers durable survival benefit for patients with ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine